These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18839307)

  • 1. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
    Viale G; Rotmensz N; Maisonneuve P; Bottiglieri L; Montagna E; Luini A; Veronesi P; Intra M; Torrisi R; Cardillo A; Campagnoli E; Goldhirsch A; Colleoni M
    Breast Cancer Res Treat; 2009 Jul; 116(2):317-28. PubMed ID: 18839307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.
    Lee Y; Cho S; Seo JH; Shin BK; Kim HK; Kim I; Kim A
    Am J Clin Pathol; 2007 Dec; 128(6):1041-9. PubMed ID: 18024331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
    J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
    van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
    Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes.
    Harłoziñska A; Bar JK; Wenderski R; Bebenek M
    In Vivo; 1996; 10(2):217-22. PubMed ID: 8744803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
    Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
    J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of prognostic factors in premenopausal women with breast cancer.
    Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
    Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
    Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
    Di Saverio S; Gutierrez J; Avisar E
    Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
    Short SM; Yoder BJ; Tarr SM; Prescott NL; Laniauskas S; Coleman KA; Downs-Kelly E; Pettay JD; Choueiri TK; Crowe JP; Tubbs RR; Budd TG; Hicks DG
    Breast J; 2007; 13(2):130-9. PubMed ID: 17319853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast.
    Park SS; Kim JE; Kim YA; Kim YC; Kim SW
    Histopathology; 2005 Dec; 47(6):625-30. PubMed ID: 16324201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.